CJC-1295 Without DAC

CJC-1295 Without DAC, also known as sermorelin acetate modified, is a 30-amino acid peptide representing a modified fragment of human GHRH(1-29). This synthetic GHRH analog features specific amino acid substitutions that confer increased resistance to enzymatic degradation compared to native GHRH. The absence of the Drug Affinity Complex (DAC) technology differentiates this variant, resulting in a shorter half-life in research settings, which can be advantageous for studies requiring more transient GHRH receptor activation. Historically, research into GHRH analogs aimed to develop compounds with improved pharmacokinetic profiles for studying growth hormone regulation. CJC-1295 Without DAC emerged from these efforts, providing a stable and potent tool for investigating the hypothalamic-pituitary axis. Its mechanism of action involves binding to the GHRH receptor on somatotroph cells in the anterior pituitary, stimulating the synthesis and pulsatile release of growth hormone. In laboratory research, CJC-1295 Without DAC is utilized to explore various aspects of growth hormone physiology, including its role in metabolic processes, tissue regeneration, and cellular proliferation. Studies often focus on understanding the precise signaling pathways activated by GHRH receptor engagement and the downstream effects on gene expression related to somatotropin production. Its application is strictly limited to controlled experimental environments to elucidate fundamental biological mechanisms.